{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T16:14:43Z","timestamp":1783700083116,"version":"3.55.0"},"reference-count":38,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Infliximab and adalimumab are the only biologics approved by the US Food and Drug Administration for use in children with inflammatory bowel disease (IBD). The comparative infection risks between infliximab and adalimumab have not been evaluated in clinical settings.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To compare the risk of infections with infliximab vs adalimumab among pediatric patients with IBD using nationwide claims data.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This cohort study used data from 2 nationwide health care claims databases from January 1, 2016, to February 28, 2025. The study included children and adolescents aged 6 to 17 years with a diagnosis of Crohn disease or ulcerative colitis who newly initiated infliximab or adalimumab and had 180 days or more of prior continuous enrollment.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Initiation of adalimumab vs infliximab.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Serious infections were defined as infections requiring hospitalization, using a validated algorithm. Outpatient infections were defined as an outpatient infection diagnosis with a targeted antimicrobial dispensed within 1 day. Baseline covariates within each dataset were balanced with 1:1 propensity score matching and results were pooled using fixed effects meta-analysis. Incidence rates and hazard ratios (HRs) were estimated over a 180-day follow-up.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n After applying exclusion criteria, 4239 children with IBD initiating infliximab (2467; mean [SD] age, 13.3 [2.9] years; 1462 boys [59.3%]; 1502 with Crohn disease [60.9%]) or adalimumab (1772; mean [SD] age, 14.0 [2.7] years; 1047 boys [59.1%]; 1068 with Crohn disease [60.3%]) were identified. After matching, each exposure group included 1533 patients. The incidence of serious infections was 29 per 1000 person-years for infliximab (reference) and 34 per 1000 person-years for adalimumab (pooled HR, 1.15; 95% CI, 0.63-2.11). Outpatient infections were more common, with rates of 358 per 1000 person-years for infliximab and 386 per 1000 person-years for adalimumab (pooled HR, 1.08; 95% CI, 0.90-1.29). Results of sensitivity analyses, including restriction to monotherapy, originator-only use, first-line users only, exclusion of gastrointestinal infections from the outcome, and extending follow-up to 365 days, were all consistent with the primary findings. No mycobacterial infections were observed in the overall cohort.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cohort study of children and adolescents with IBD, serious infections were rare. No evidence of differences in infection risk were observed between infliximab and adalimumab. These findings suggest that the 2 agents may have comparable infection risk profiles in pediatric IBD, although meaningful differences cannot be ruled out.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.22684","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T15:30:19Z","timestamp":1783697419000},"page":"e2622684","source":"Crossref","is-referenced-by-count":0,"title":["Risk of Infections With Infliximab vs Adalimumab Among Children With Inflammatory Bowel Disease"],"prefix":"10.1001","volume":"9","author":[{"given":"Ning","family":"Lyu","sequence":"first","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Harvard-MIT Center for Regulatory Science, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Tracy","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Hepatology, and Nutrition, Boston Children\u2019s Hospital, Boston, Massachusetts"},{"name":"Department of Pediatrics, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Schneeweiss","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Department of Medicine, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J.","family":"Savage","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Department of Medicine, Harvard Medical School, Boston, Massachusetts"},{"name":"Division of Infectious Diseases, Boston Children\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"issue":"5","key":"zoi260630r1","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1053\/j.gastro.2024.11.004","article-title":"Prevalence of pediatric inflammatory bowel disease in the United States: pooled estimates from three administrative claims data sources.","volume":"168","author":"Kappelman","year":"2025","journal-title":"Gastroenterology"},{"issue":"5","key":"zoi260630r2","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1097\/MPG.0000000000003734","article-title":"Use, durability, and risks for discontinuation of initial and subsequent biologics in a large pediatric-onset IBD cohort.","volume":"76","author":"Kaplan","year":"2023","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"3","key":"zoi260630r3","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1053\/j.gastro.2006.12.003","article-title":"Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn\u2019s disease in children.","volume":"132","author":"Hyams","year":"2007","journal-title":"Gastroenterology"},{"issue":"4","key":"zoi260630r4","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.cgh.2011.11.026","article-title":"Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis.","volume":"10","author":"Hyams","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"zoi260630r5","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1053\/j.gastro.2012.04.046","article-title":"Safety and efficacy of adalimumab for moderate to severe Crohn\u2019s disease in children.","volume":"143","author":"Hyams","year":"2012","journal-title":"Gastroenterology"},{"issue":"8","key":"zoi260630r6","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/S2468-1253(21)00142-4","article-title":"Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study.","volume":"6","author":"Croft","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"zoi260630r7","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jpeds.2021.06.076","article-title":"Serious infections in pediatric inflammatory bowel disease 2002-2017\u2014a nationwide cohort study.","volume":"238","author":"Ludvigsson","year":"2021","journal-title":"J Pediatr"},{"issue":"9","key":"zoi260630r8","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1111\/apt.13580","article-title":"Comparative effectiveness and safety of infliximab and adalimumab in patients with ulcerative colitis.","volume":"43","author":"Singh","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"zoi260630r9","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1016\/j.cgh.2016.11.024","article-title":"Comparison of infliximab and adalimumab in biologic-naive patients with ulcerative colitis: a nationwide Danish cohort study.","volume":"15","author":"Singh","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"zoi260630r10","doi-asserted-by":"publisher","first-page":"S-365","DOI":"10.1016\/S0016-5085(18)31535-X","article-title":"1711\u2014Real world comparative risk of serious infection with adalimumab, vedolizumab, and infliximab in patients with inflammatory bowel disease.","volume":"154","author":"Osterman","year":"2018","journal-title":"Gastroenterology"},{"issue":"3","key":"zoi260630r11","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.1093\/jcag\/gwz018","article-title":"Canadian Association of Gastroenterology clinical practice guideline for the medical management of pediatric luminal Crohn\u2019s disease.","volume":"2","author":"Mack","year":"2019","journal-title":"J Can Assoc Gastroenterol"},{"issue":"2","key":"zoi260630r12","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1093\/ecco-jcc\/jjaa161","article-title":"The medical management of paediatric Crohn\u2019s disease: an ECCO-ESPGHAN guideline update.","volume":"15","author":"van Rheenen","year":"2021","journal-title":"J Crohns Colitis"},{"issue":"10","key":"zoi260630r13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0040297","article-title":"Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration.","volume":"4","author":"Vandenbroucke","year":"2007","journal-title":"PLoS Med"},{"issue":"5","key":"zoi260630r14","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1093\/ibd\/izac131","article-title":"A systematic review of Crohn\u2019s disease case definitions in administrative or claims databases.","volume":"29","author":"Hutfless","year":"2023","journal-title":"Inflamm Bowel Dis"},{"issue":"7","key":"zoi260630r15","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1002\/pds.5253","article-title":"Validity of ICD-10-CM diagnoses to identify hospitalizations for serious infections among patients treated with biologic therapies.","volume":"30","author":"Lo Re","year":"2021","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"zoi260630r16","doi-asserted-by":"publisher","first-page":"e964","DOI":"10.1542\/peds.2012-3488","article-title":"The diagnosis and management of acute otitis media.","volume":"131","author":"Lieberthal","year":"2013","journal-title":"Pediatrics"},{"issue":"1","key":"zoi260630r17","doi-asserted-by":"publisher","first-page":"e262","DOI":"10.1542\/peds.2013-1071","article-title":"Clinical practice guideline for the diagnosis and management of acute bacterial sinusitis in children aged 1 to 18 years.","volume":"132","author":"Wald","year":"2013","journal-title":"Pediatrics"},{"issue":"10","key":"zoi260630r18","first-page":"2065","volume":"63","author":"Preboth","year":"2001","journal-title":"Am Fam Physician"},{"issue":"4","key":"zoi260630r19","doi-asserted-by":"publisher","DOI":"10.1093\/crocol\/otab076","article-title":"Persistence, dosing, and other treatment patterns among Crohn\u2019s disease patients initiating biologics in United States.","volume":"3","author":"Teeple","year":"2021","journal-title":"Crohns Colitis 360"},{"issue":"5","key":"zoi260630r20","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1093\/aje\/kwaa244","article-title":"Development and validation of a pediatric comorbidity index.","volume":"190","author":"Sun","year":"2021","journal-title":"Am J Epidemiol"},{"key":"zoi260630r21","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.6325","author":"Schneeweiss","year":"2023","journal-title":"JAMA Dermatol"},{"issue":"6","key":"zoi260630r22","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1080\/03610910902859574","article-title":"Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research.","volume":"38","author":"Austin","year":"2009","journal-title":"Commun Stat Simul Comput"},{"issue":"4","key":"zoi260630r23","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1097\/EDE.0b013e3181a663cc","article-title":"High-dimensional propensity score adjustment in studies of treatment effects using health care claims data.","volume":"20","author":"Schneeweiss","year":"2009","journal-title":"Epidemiology"},{"issue":"11","key":"zoi260630r24","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1001\/jama.2023.15503","article-title":"Treatment failure and adverse events after amoxicillin-clavulanate vs amoxicillin for pediatric acute sinusitis.","volume":"330","author":"Savage","year":"2023","journal-title":"JAMA"},{"issue":"6","key":"zoi260630r25","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2020-033316","article-title":"Fluoroquinolone antibiotics and tendon injury in adolescents.","volume":"147","author":"Ross","year":"2021","journal-title":"Pediatrics"},{"issue":"3","key":"zoi260630r26","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1002\/cpt.329","article-title":"Transparency and reproducibility of observational cohort studies using large healthcare databases.","volume":"99","author":"Wang","year":"2016","journal-title":"Clin Pharmacol Ther"},{"issue":"16","key":"zoi260630r27","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1001\/jama.2023.4221","article-title":"Emulation of randomized clinical trials with nonrandomized database analyses: results of 32 clinical trials.","volume":"329","author":"Wang","year":"2023","journal-title":"JAMA"},{"issue":"2","key":"zoi260630r28","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1080\/00031305.2016.1154108","article-title":"The ASA\u2019s statement on P values: context, process, and purpose.","volume":"70","author":"Wasserstein","year":"2016","journal-title":"Am Stat"},{"issue":"9","key":"zoi260630r29","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1016\/j.cgh.2014.01.021","article-title":"Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review.","volume":"12","author":"Dulai","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"23","key":"zoi260630r30","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis.","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med"},{"issue":"9317","key":"zoi260630r31","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial.","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"issue":"9","key":"zoi260630r32","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1056\/NEJMoa030815","article-title":"Infliximab maintenance therapy for fistulizing Crohn\u2019s disease.","volume":"350","author":"Sands","year":"2004","journal-title":"N Engl J Med"},{"issue":"9","key":"zoi260630r33","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1136\/gut.2006.106781","article-title":"Adalimumab for maintenance treatment of Crohn\u2019s disease: results of the CLASSIC II trial.","volume":"56","author":"Sandborn","year":"2007","journal-title":"Gut"},{"issue":"2","key":"zoi260630r34","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1053\/j.gastro.2011.10.032","article-title":"Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis.","volume":"142","author":"Sandborn","year":"2012","journal-title":"Gastroenterology"},{"issue":"5","key":"zoi260630r35","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1053\/j.gastro.2012.01.035","article-title":"Adalimumab induces and maintains mucosal healing in patients with Crohn\u2019s disease: data from the EXTEND trial.","volume":"142","author":"Rutgeerts","year":"2012","journal-title":"Gastroenterology"},{"issue":"17","key":"zoi260630r36","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1001\/jama.2016.4151","article-title":"Prevalence of inappropriate antibiotic prescriptions among US ambulatory care visits, 2010-2011.","volume":"315","author":"Fleming-Dutra","year":"2016","journal-title":"JAMA"},{"issue":"10","key":"zoi260630r37","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.37409","article-title":"Optimal pediatric outpatient antibiotic prescribing.","volume":"7","author":"Lehrer","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"4","key":"zoi260630r38","doi-asserted-by":"publisher","first-page":"e956","DOI":"10.1542\/peds.2014-0605","article-title":"Bacterial prevalence and antimicrobial prescribing trends for acute respiratory tract infections.","volume":"134","author":"Kronman","year":"2014","journal-title":"Pediatrics"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2851535\/lyu_2026_oi_260630_1783018028.99176.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T15:30:20Z","timestamp":1783697420000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2851535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":38,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.22684","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]}}}